Introduction
Introduction Statistics Contact Development Disclaimer Help
Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
Return to: BETASERON (interferon beta-1b, Betaferon, Extavia)
*****************************************************
#Post#: 948--------------------------------------------------
(MSAA) Electronic autoinjector approved for Betaseron
By: agate Date: September 28, 2015, 7:47 pm
---------------------------------------------------------
From the MSAA news update, September 28, 2015:
[quote]Electronic Autoinjector Approved for Betaseron
On September 25, 2015, the United States Food and Drug
Administration (FDA) approved Betaconnect, an electronic
autoinjector for use with Betaseron� (interferon beta-1b), an
approved disease-modifying therapy (DMT) for the treatment of
relapsing-remitting multiple sclerosis (RRMS). Although other
autoinjectors are available to help with the administration of
self-injected medications, this is the first electronic
autoinjector to be approved by the FDA for a medication used in
the long-term treatment of multiple sclerosis (MS). Marketed by
parent company Bayer HealthCare, this device will be available
in early 2016.
Betaseron is given via subcutaneous (under the skin)
self-injections every other day. According to Bayer HealthCare,
the electronic autoinjector was developed based on feedback from
individuals with MS and their caregivers. The features of this
new device include:
~customizable injection speed and depth settings that allow
individuals to inject quietly and with precision at the touch of
a button
~optional back-up reminder function to alert those using this
device that it�s time for their next injection
~automatic needle insertion and retraction
~visual and audio end-of-dose indication to confirm when the
injection is complete
Bayer HealthCare states that after completing the preparation of
Betaseron, individuals may use Betaconnect, but this should only
be done with the syringes provided in the Betaseron packaging.
They also caution that those using Betaconnect should speak to a
healthcare provider or nurse before making any changes to their
injection depth or speed settings.
MSAA President and CEO Doug Franklin explains, �Providing new
options to assist with the administration of an MS medication is
important. When ease and comfort are increased, and reminders
are given when the next dose is due, individuals may be better
able to stay on course with their treatment plan.�
For those taking a disease-modifying therapy for the long-term
treatment of MS, research shows that adhering to one�s treatment
regimen is critical to experiencing the best health outcomes.
The approval of Betaconnect, as well as any device or method
that enables individuals to stay on their prescribed treatment
with fewer interruptions, is greatly welcomed by the MS
community.
For more information or to speak with a trained Client Services
Specialist, please call MSAA's Helpline at (800) 532-7667,
extension 154. Questions to MSAA's Client Services department
may also be emailed to [email protected].
_______________________
Written by Susan Wells Courtney, MSAA Senior Writer and Creative
Director
Reviewed by Jack Burks, MD, MSAA Chief Medical Officer[/quote]
*****************************************************
You are viewing proxied material from gopher.createaforum.com. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.